149 FIFTH AVENUE, NEW YORK, NY
Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
CFO Departure - Alexander Arrow Terminated Effective April 30, 2026
William Nichols Appointed President of Protagenic Therapeutics, Inc.
Settlement Agreement with Alterola Biotech Inc. Finalized on February 17, 2026
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Announces Receipt of Nasdaq Non-Compliance Notice
Director Resignation - Jennifer Chao Steps Down from Board
Investor Presentation
Q2
Notice of Late Filing for Quarterly Report
FY 2025
Q0
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notification Filed by a National Security Exchange
Quarterly Report Transition
Correspondence